Gastroenterology · Cirrhosis Complications
The facts most likely to be tested
Hepatorenal syndrome is a diagnosis of exclusion characterized by progressive renal failure in patients with advanced cirrhosis and ascites.
The underlying pathophysiology involves splanchnic vasodilation leading to systemic hypotension and subsequent renal vasoconstriction.
Patients present with a low urine sodium (<10 mmol/L) and lack of significant proteinuria, distinguishing it from acute tubular necrosis.
The first-line pharmacological treatment is the combination of intravenous albumin and a vasoconstrictor such as terlipressin or midodrine/octreotide.
A fluid challenge with albumin is required to rule out prerenal azotemia before confirming the diagnosis of hepatorenal syndrome.
Hepatorenal syndrome is classified as a functional renal failure because there is no evidence of structural kidney damage on biopsy.
The only definitive treatment and long-term cure for hepatorenal syndrome is liver transplantation.
Vignette unlocked
A 58-year-old male with a history of alcohol-associated cirrhosis presents with increasing abdominal girth and confusion. Physical exam reveals tense ascites, jaundice, and spider angiomata. Laboratory studies show a serum creatinine of 2.4 mg/dL, up from 0.9 mg/dL one week ago. Urinalysis is bland with a urine sodium of 8 mmol/L and no casts. The patient has not received any nephrotoxic agents or diuretics recently.
What is the most appropriate initial pharmacological management for this patient?
Intravenous albumin and terlipressin
The patient's presentation of acute kidney injury in the setting of cirrhosis with a low urine sodium is classic for hepatorenal syndrome, which is managed with vasoconstrictors and albumin to reverse splanchnic vasodilation.
Full handout
High yield triage
Etiology / Epidemiology
Occurs in patients with advanced cirrhosis and ascites due to systemic vasodilation and renal vasoconstriction.
Clinical Manifestations
Presents as azotemia in a cirrhotic patient; oliguria is the hallmark clinical sign.
Diagnosis
Diagnosis of exclusion; serum creatinine >1.5 mg/dL with no improvement after 48 hours of albumin resuscitation.
Treatment
First-line is midodrine plus octreotide combined with IV albumin; liver transplant is the only definitive cure.
Prognosis
Extremely poor; median survival is often measured in weeks without transplant.
Full handout
Epidemiology & Etiology
Hepatorenal syndrome (HRS) is a functional renal failure occurring in patients with decompensated cirrhosis. It is frequently precipitated by spontaneous bacterial peritonitis or aggressive diuretic use. It represents a state of extreme splanchnic vasodilation leading to reduced effective arterial blood volume.
Pertinent Anatomy
The pathology centers on the renal artery and the splanchnic circulation. Systemic vasodilation in the gut leads to a compensatory, yet maladaptive, renal vasoconstriction.
Pathophysiology
Cirrhosis leads to portal hypertension and the release of vasodilators like nitric oxide. This causes systemic hypotension, triggering the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. The resulting intense renal cortical vasoconstriction causes a rapid decline in the glomerular filtration rate despite structurally normal kidneys.
Clinical Manifestations
Patients present with progressive oliguria and rising creatinine in the setting of ascites. Red flags include rapid onset of confusion or worsening jaundice. Physical exam often reveals stigmata of chronic liver disease, such as spider angiomata and palmar erythema.
Diagnosis
Diagnosis requires a serum creatinine >1.5 mg/dL that fails to improve after 48 hours of diuretic withdrawal and albumin expansion (1g/kg/day). One must rule out acute tubular necrosis (ATN) via urinalysis, which typically shows fractional excretion of sodium (FeNa) <1% in HRS, unlike the >2% seen in ATN.
Treatment
The primary goal is to increase systemic vascular resistance. Midodrine (alpha-agonist) and octreotide (somatostatin analog) are the first-line agents used to reverse splanchnic vasodilation. Contraindications for vasoconstrictors include active coronary artery disease. IV albumin is mandatory to maintain oncotic pressure. The only definitive treatment is liver transplantation.
Prognosis
The prognosis is dismal without intervention, with median survival often less than 3 months. Patients require close monitoring of fluid intake/output and electrolytes. HRS is a major predictor of mortality in patients awaiting liver transplant.
Differential Diagnosis
Acute Tubular Necrosis: FeNa >2% and muddy brown casts
Prerenal Azotemia: Responds rapidly to fluid resuscitation
Acute Interstitial Nephritis: Presence of eosinophiluria and drug exposure
Glomerulonephritis: Presence of hematuria and RBC casts
Obstructive Uropathy: Hydronephrosis on renal ultrasound